Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma

Roy E. Strowd; Inas A. Abuali; Stuart A. Grossman

doi:10.2217/cns.15.3

Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma

Roy E. Strowd, Inas A. Abuali, Stuart A. Grossman

School of Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who failed systemic rituximab and could not tolerate IT chemotherapies, but had an objective response of 6 months duration to IT rituximab.

Original language	English (US)
Pages (from-to)	131-135
Number of pages	5
Journal	CNS oncology
Volume	4
Issue number	3
DOIs	https://doi.org/10.2217/cns.15.3
State	Published - 2015

Keywords

CNS lymphoma
indolent lymphoma
intrathecal rituximab
low-grade lymphoma

ASJC Scopus subject areas

Clinical Neurology
Neurology

Access to Document

10.2217/cns.15.3

Cite this

@article{43fffcfb43424808a710bf2ae86585c8,

title = "Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma",

abstract = "Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who failed systemic rituximab and could not tolerate IT chemotherapies, but had an objective response of 6 months duration to IT rituximab.",

keywords = "CNS lymphoma, indolent lymphoma, intrathecal rituximab, low-grade lymphoma",

author = "Strowd, {Roy E.} and Abuali, {Inas A.} and Grossman, {Stuart A.}",

year = "2015",

doi = "10.2217/cns.15.3",

language = "English (US)",

volume = "4",

pages = "131--135",

journal = "CNS oncology",

issn = "2045-0915",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma

AU - Strowd, Roy E.

AU - Abuali, Inas A.

AU - Grossman, Stuart A.

PY - 2015

Y1 - 2015

N2 - Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who failed systemic rituximab and could not tolerate IT chemotherapies, but had an objective response of 6 months duration to IT rituximab.

AB - Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who failed systemic rituximab and could not tolerate IT chemotherapies, but had an objective response of 6 months duration to IT rituximab.

KW - CNS lymphoma

KW - indolent lymphoma

KW - intrathecal rituximab

KW - low-grade lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85050578404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050578404&partnerID=8YFLogxK

U2 - 10.2217/cns.15.3

DO - 10.2217/cns.15.3

M3 - Article

C2 - 25905905

AN - SCOPUS:85050578404

SN - 2045-0915

VL - 4

SP - 131

EP - 135

JO - CNS oncology

JF - CNS oncology

IS - 3

ER -

Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this